Diamondback Energy Inc vs Twist Bioscience Corp — how do they compare? Diamondback Energy Inc trades at $201 (market cap $56.48B), while Twist Bioscience Corp trades at $123.76 (market cap $7.72B). The key difference: Diamondback Energy Inc is far larger — about 7.3× Twist Bioscience Corp's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| FANG | TWST | |
|---|---|---|
Market Cap | $56.48B | $7.72B |
Sector | Energy | Health |
52-Week High | $213.69 | $124.88 |
52-Week Low | $134.53 | $24.16 |
Enterprise Value | $68.63B | $7.65B |
Dividend Yield | 2.18% | — |
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $200.97, up 1.01% with strong bullish technical signals and positive earnings momentum. The company delivered Q2 2026 EPS of $6.48, beating estimates by 6.6%, while revenue growth accelerated to $14.93B in 2025. Analyst consensus remains overwhelmingly bullish with 90% buy ratings and a $236.63 price target, representing 18% upside potential. Recent news highlights operational excellence and production growth guidance increases.
The outlook remains positive with production growth and debt reduction supporting valuation expansion. Key risks include oil price volatility and execution challenges amid global supply disruptions. Institutional interest remains strong with recent positions from Balefire LLC, though some trimming occurred from Bank of Nova Scotia. The combination of earnings beats, improved guidance, and favorable technicals suggests continued upward momentum.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Trailing returns across standard periods
Latest headlines on both assets
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →